Leap Therapeutics starts randomized Part B of DKN-01 Phase 2 CRC study after positive Part A

CYPHERPUNK TECHNOLOGIES INC.

Initiated 130-patient randomized controlled Part B of DeFianCe study of DKN-01 in second-line advanced colorectal cancer.
Part A enrolled 33 aggressive CRC patients and exceeded 20% overall response rate, triggering Part B.
Primary endpoint of Part B is progression-free survival; enrollment expected ~12 months, data late 2024.
Regained Nasdaq compliance with minimum bid price rule after 11 consecutive days above $1.00 (July 6, 2023).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.